EUVIMEDOpdag EUVIMED
BeobachtungsstudieVergleichsstudieKohortenstudieOpen access · CC BY-NC-ND 4.0

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study

David W Dodick iD, Stewart J Tepper, Jessica Ailani, Ani C Khodavirdi, Nico Pannacciulli, Alan Fu, Shia T Kent, Karminder Gill, Robert Urman, Sam S Oh

Headache: The Journal of Head and Face Pain · 2025-06 · 65 (6) · 919-932

DOI: 10.1111/head.14912 ↗

At a glance

Beobachtungsstudie in Headache: The Journal of Head and Face Pain, published online on 2025-03-03. Written by David W Dodick and 9 co-authors. Institution: Mayo Clinic, Scottsdale, Arizona, USA. Major MEDLINE topics: Migraine Disorders, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists, Cardiovascular Diseases. Cited 8 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novartis, Amgen Inc., Amgen.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To estimate the real‐world risk of cardiovascular events among patients with migraine treated with erenumab and other migraine preventive medications.

Background

Migraine preventive treatment with calcitonin gene‐related peptide (CGRP) pathway inhibitors, such as erenumab and others, may theoretically result in cardiovascular effects due to a lack of compensatory vasodilation with CGRP pathway inhibition.

Methods

In this retrospective observational cohort study, we estimated the unadjusted cumulative risk (CR) of new‐onset hypertension, acute myocardial infarction (MI), or stroke among patients with migraine newly treated with erenumab, other anti‐CGRP pathway monoclonal antibodies (mAbs), standard oral preventive medications, and onabotulinumtoxinA using data from the MarketScan® Commercial and Medicare Supplemental medical claims database. Comparative analyses to assess the relative risk (RR) of vascular events were gated on the comparability of treatment groups with respect to baseline demographics and clinical characteristics. Potential bias due to unmeasured confounding was evaluated via negative control outcome (NCO) analyses. Confounding based on measured covariates and differential informative censoring were addressed with inverse probability weights.

Results

A total of 108,019 new users of migraine preventive medications were included. Unadjusted CR (95% confidence interval [CI]) of hypertension at 12 months of treatment was: erenumab, 9.34% (8.79–9.89%); other anti‐CGRP pathway mAbs, 9.42% (8.92–9.92%); standard oral preventive medications, 9.09% (8.77–9.41%); and onabotulinumtoxinA, 9.10% (8.39–9.81%). NCO analyses identified minimal concerns related to unmeasured confounding in erenumab versus other mAbs and erenumab versus onabotulinumtoxinA comparisons. Adjusted RRs (95% CIs) of acute MI and stroke, respectively, at 36 months of treatment were 1.02 (0.45–1.59) and 0.90 (0.56–1.25) for erenumab versus other mAbs and 0.87 (0.19–1.55) and 0.97 (0.42–1.52) for erenumab versus onabotulinumtoxinA.

Conclusions

In this analysis of the MarketScan medical claims database, we found no difference in the risk of vascular events in patients treated with erenumab versus other anti‐CGRP pathway mAbs or onabotulinumtoxinA.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsCardiovascular DiseasesHypertensionMyocardial InfarctionStrokeHumansUnited StatesMaleFemaleMiddle AgedRetrospective StudiesAdultDatabases, FactualCohort StudiesBotulinum Toxins, Type AAged

Author keywords

acute myocardial infarctioncardiovascularerenumabhypertensionstroke

Substances

erenumabAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsBotulinum Toxins, Type Aonabotulinum toxin A

Authors and institutions

  • Mayo Clinic, Scottsdale, Arizona, USA.
  • New England Institute for Neurology and Headache, Stamford, Connecticut, USA.
  • Department of Neurology, MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
  • Amgen Inc., Thousand Oaks, California, USA.

ORCID profiles: David W Dodick

Funding

  • Novartis
  • Amgen Inc.
  • Amgen

Cite

APA

Dodick, D. W., Tepper, S. J., Ailani, J., Khodavirdi, A. C., Pannacciulli, N., Fu, A., Kent, S. T., Gill, K., Urman, R., & Oh, S. S. (2025). Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study. Headache: The Journal of Head and Face Pain, 65(6), 919-932. https://doi.org/10.1111/head.14912

Vancouver

Dodick DW, Tepper SJ, Ailani J, Khodavirdi AC, Pannacciulli N, Fu A, et al. Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study. Headache: The Journal of Head and Face Pain. 2025;65(6):919-932. doi:10.1111/head.14912

BibTeX
@article{Dodick2025,
  author = {Dodick, David W and Tepper, Stewart J and Ailani, Jessica and Khodavirdi, Ani C and Pannacciulli, Nico and Fu, Alan and Kent, Shia T and Gill, Karminder and Urman, Robert and Oh, Sam S},
  title = {Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  volume = {65},
  number = {6},
  pages = {919--932},
  doi = {10.1111/head.14912}
}
Start for free →